NHS England recommends extension of drug to treat non-metastatic prostate cancer
Abstract
Men in England with non-metastatic prostate cancer can be prescribed abiraterone acetate (Zytiga; Janssen Biotech) on the NHS. In guidance published on 16 January 2026, NHS England said that abiraterone acetate can be prescribed off-label to men with high-risk, hormone sensitive, non-metastatic cancer. “Around 2,000 men diagnosed with prostate cancer in the last three months […]
Fields of Study & Subjects
Prostate Cancer Treatment and Research
Prostate Cancer Diagnosis and Treatment
Bone health and treatments
Publication details
- Journal / source
- Pharmaceutical journal/The pharmaceutical journal
- Publication date
- 1 January 2026